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A novel antioxidant for the potential treatment of ischaemia was designed by incorporating an 
isoindoline nitroxide into the framework of the free radical scavenger edaravone. 5-(3-
Methyl-pyrazol-5-ol-1-yl)-1,1,3,3-tetramethylisoindolin-2-yloxyl 7 was prepared by N-
arylation of 3-methyl-5-pyrazolone with 5-iodo-1,1,3,3-tetramethylisoindoline-2-yloxyl 8 in 
the presence of catalytic copper(I)iodide. Evaluation of 7, its methoxyamine derivative 10 and 
5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl (CTMIO) against edaravone 1 in ischaemic 
rat atrial cardiomyocytes revealed significant decreases in cell death after prolonged 
ischaemia for each agent; however the protective effect of the novel antioxidant 7 (showing 
greater than 85% reduction in cell death at 100 μM) was significantly enhanced over that of 
edaravone 1 alone. Furthermore, the activity for 7 was found to be equal to or greater than the 
potent cardioprotective agent N
6
-cyclopentyladenosine (CPA). The methoxyamine adduct 10 
and edaravone 1 showed no difference between the extent of reduction in cell death whilst 
CTMIO had only a modest protective effect.  
 
Introduction 
Ischaemia is a feature of both stroke and myocardial infarction and results in an inadequate 
supply of blood and oxygen to the brain or heart. The severity of brain or heart damage 
resulting from an ischaemic event depends on the degree and duration of ischaemia. It is 
therefore critical to shorten the ischaemic time in patients with cerebral or myocardial 
infarction in order to improve their immediate and long-term outcomes. Well established 
therapeutic strategies to limit infarct size involve early reperfusion with percutaneous 
coronary intervention (PCI) or thrombolytic therapy (administration of tissue plasminogen 
activator) and stabilization with antiplatelet agents.
1, 2
 However, these strategies alone are not 
sufficient to prevent neuronal dysfunction or myocardial injury as reactive oxygen species 
(ROS) are generated both during ischaemia
3
 and when oxygen is reintroduced to ischaemic 
tissue (reperfusion injury).
4, 5
 
 
 Oxidative stress plays a crucial role in neurodegenerative, cerebrovascular and 
cardiovascular diseases. Under pathological conditions such as brain and heart injuries where 
energy generation is suppressed, the production of excessive reactive oxygen species (ROS) 
such as hydrogen peroxide (H2O2), hydroxyl radical (HO
•
) and superoxide anion radical (O2
•-
) 
can induce further damage to cell membranes, resulting in the development of cerebral 
edema, infarction
6
 and left ventricular dysfunction.
7, 8
 Thus, the protection of cells from ROS 
attacks is considered to be an important therapeutic target during the acute phases of stroke 
and heart attack. 
 
 Edaravone (3-methyl-1-phenyl-2-pyrizolin-5-one) 1 is a free radical scavenger that has 
been approved for use in ischaemic stroke patients in Japan since 2001.
9
 The neuroprotective 
effects of edaravone 1 result from its ability to prevent impairment of the antioxidant defence 
system by reducing or restoring the amount of ROS increased by post-ischaemic 
reperfusion.
10-12
 By trapping hydroxyl radicals, edaravone 1 causes enhancement of 
prostacyclin production,
13
 radio-protection against ionizing radiation
14, 15
 and the inhibition of 
both lipid peroxidation
16
 and the lipoxygenase pathway.
13
 The putative mechanism 
underlying the antioxidant action of edaravone 1 involves the transfer of electrons from the 
edaravone anion 2 to a peroxyl radical, yielding an edaravone radical 3 and a peroxyl anion 
(Scheme 1). Subsequently, the edaravone radical 3 forms a peroxyl radical of edaravone 4, 
which is transformed into a 4,5-dione 5 and then hydrolysed to afford 2-oxo-3-
(phenylhydrazone)-butanoic acid 6.
17
  
 
Insert Scheme 1 here 
 
 The administration of edaravone 1 to rats after myocardial ischaemia-reperfusion also 
provided protection against the deterioration of cardiac function and suppressed the 
occurrence of lethal ventricular tachyarrhythmia.
18
 In addition, a reduction in myocardial 
infarction size following ischaemia-reperfusion has also been observed in rabbits upon 
treatment with edaravone 1.
19, 20
 In patients with acute myocardial infarction, the 
administration of edaravone 1 before reperfusion was associated with smaller infarcts and 
better clinical outcomes.
21, 22
 
 
 In addition to edaravone 1, other antioxidants have been attracting interest in recent years 
as increased levels of oxidative stress are implicated in many disease states, including 
Alzheimer’s disease, Parkinson’s disease, cardiovascular disease, cancer and aging. 
Nitroxides, a class of stable free radicals, are commonly used as potent antioxidants in 
biological systems.
23, 24
 Their redox and radical trapping properties can lower levels of 
oxidative stress in cellular systems caused by ROS
25-29
 and they can also provide radio-
protection towards ionising radiation.
30-32
 Nitroxides can also function as superoxide 
dismutase mimetics.
33
 A number of different ring class nitroxides have been used in mouse 
models of stroke and other ischaemic injuries (including cardioprotection from ischaemia-
reperfusion)
34, 35
 and have been shown to decrease the resultant infarct volume presumably 
via an antioxidant mode of action.
36-38 
A recent trend in medicinal chemistry research has 
been to combine tested and established pharmacophores within the one molecule.
39
 The work 
presented here reflects this approach and describes the synthesis and evaluation of a novel 
antioxidant, 5-(3-methyl-pyrazol-5-ol-1-yl)-1,1,3,3-tetramethylisoindolin-2-yloxyl 7, as a 
potential new treatment for cardiovascular ischaemia. This novel antioxidant was prepared by 
incorporating an isoindoline nitroxide into the edaravone framework.  
 
Results and Discussion 
Synthesis 
A number of routes were available for the synthesis of the target molecule, 5-(3-methyl-5-
pyrazolone-1-yl)-1,1,3,3-tetramethylisoindolin-2-yloxyl 7. The parent edaravone compound 1 
is typically prepared by the thermal condensation of phenyl hydrazine with ethyl 
acetoacetate.
40
 However, the corresponding 1,1,3,3-tetramethylisoindolin-2-yloxyl hydrazine 
analogue was envisioned to be unstable as hydrazines commonly reduce nitroxides to their 
corresponding hydroxylamines.
41
 Instead, a more concise synthesis which circumvented this 
unfavourable interaction was pursued. Transition metal catalysed N-arylation of amides using 
aryl halides is well known in the literature.
42-47
 In these C-N bond forming reactions, 
palladium and copper are the most commonly encountered catalysts. Associated ligands are 
generally phosphorus-based for palladium
45
 and chelating diamine ligands for copper
48
 but 
N-O mixed ligands are also used.
46
 
 
 We have previously utilized halogenated nitroxides such as 5-bromo-1,1,3,3-
tetramethylisoindoline-2-yloxyl and 5-iodo-1,1,3,3-tetramethylisoindoline-2-yloxyl 8 in 
palladium-catalysed Heck, Suzuki and Sonogashira cross-couplings.
49-51
 As an alternative 
route to the target molecule 7, we explored the use of halogenated nitroxides for C-N 
amidation reactions. Using the conditions of Filipski,
46
 the reaction of 3-methyl-5-pyrazolone 
with 5-bromo-1,1,3,3-tetramethylisoindoline-2-yloxyl in the presence of the ligand 8-
hydroxyquinoline, potassium carbonate and catalytic copper (I) iodide in DMSO at 120
o
C for 
96 hours gave unreacted starting materials. However, use of the more reaction iodo nitroxide 
8 gave the desired product 7 in a low isolated yield (13%) after reacting at 130
o
C for 3 hours. 
As a marked colour change was observed in this reaction at around 85
o
C, the reaction was 
repeated at 95
o
C in an attempt to increase the yield of the desired product 7. After 8 hours at 
this temperature, TLC analysis revealed complete consumption of starting materials, yet the 
isolated yield of 7 did not improve (Scheme 2). A large mass of a highly polar residue was, 
however, observed upon work-up. Subsequent variations to these reaction conditions 
including the use of the iodo amine, 5-iodo-1,1,3,3-tetramethylisoindoline, or the acetate 
protected iodo nitroxide, 2-acetoxy-5-iodo-1,1,3,3-tetramethylisoindoline, failed to improve 
the yield any further.  
 
Insert Scheme 2 here 
 
The use of the N-arylation conditions of Taillefer
42
 was also explored. Surprisingly, the 
reaction of 3-methyl-5-pyrazolone with iodo nitroxide 8 in the presence of Fe(acac)3, 
catalytic CuO and potassium carbonate in DMF at 90
o
C for 48 hours gave the corresponding 
secondary amine, 5-iodo-1,1,3,3-tetramethylisoindoline 9, in good yield (74%) (Scheme 3). 
This reduction did not occur in the absence of 3-methyl-5-pyrazolone and both metals 
together with 3-methyl-5-pyrazolone gave a far superior conversion of nitroxide 8 to 
secondary amine 9 than either metal on its own with 3-methyl-5-pyrazolone. Interestingly, 
this yield is significantly higher than the typical Fe/AcOH procedure for the reduction of 
nitroxides to amines (~ 30-65%).
24-26
 Nonetheless, the only C-N amidation method providing 
access to the potential antioxidant 7 requires the use of 8-hydroxyquinoline, potassium 
carbonate and catalytic copper (I) iodide in DMSO.  
 
Insert Scheme 3 here 
 
 Synthesis of the methoxyamine analogue of 7, 5-(3-methyl-pyrazol-5-ol-1-yl)-2-methoxy-
1,1,3,3-tetramethylisoindoline 10, was achieved in good yield (69%) from 7 using methyl 
radicals generated from DMSO, ferrous ions and hydrogen peroxide and provided further 
evidence for the formation of 7 (Scheme 2). Interestingly, 
13
C NMR analysis of 
methoxyamine 10 using DEPT revealed that the pyrazolone ring exists exclusively as the 
enol tautomer in CDCl3, whereas the parent edaravone 1 exists exclusively as the keto 
tautomer. As the enol tautomer is thought to be the active constituent of edaravone 1,
52
 this 
observation indicates that 7 has potential to be a more potent in vitro/in vivo antioxidant that 
the parent edaravone compound 1.  
 
Cardioprotective Effects 
Cultured H9c2 embryonic rat atrial cardiomyocytes were exposed to conditions used 
previously to mimic in vivo ischaemia.
34, 35, 53, 54
 This type of ischaemic model results in 
membrane dysfunction and allows entry of the fluorophore propidium iodide. Under 
simulated ischaemia conditions, 10-50 % of all cells were stained positively for propidium 
iodide. The ischaemia model proceeded as per past experience,
34, 53, 54
 with reproducible 
levels of cell death occurring after 12 hours of oxygen deprivation and metabolic stress. 
When cells were incubated in the simulated ischaemia conditions in the presence of 
edaravone 1, edaravone-TMIO 7, edaravone-TMIO-Me 10 and 5-carboxy-1,1,3,3-
tetramethylisoindolin-2-yloxyl (CTMIO),
55
 significant decreases in H9c2 cell death after 
prolonged ischaemia were observed for each agent (Figure 1). The maximal protective effect 
observed from all treatments was a reduction in cell death of 85.54 + 2.13 % produced by 100 
μM edaravone-TMIO 7. The addition of the TMIO functional group significantly enhanced 
the protective effect of edaravone 1 (two-way ANOVA, p<0.05, Figure 1). The additional 
protection provided by the TMIO was not observed for the methoxyamine adduct edaravone-
TMIO-Me 10; there was no significant difference between the extent of reduction in cell 
death produced by edaravone 1 to that produced by edaravone-TMIO-Me 10 (two-way 
ANOVA, p>0.05). In fact, there was a trend towards the methoxyamine adduct 10 having 
lower activity than edaravone 1, possibly due to greater non-polar character in the side chain 
over the parent compound. The nitroxide (CTMIO) alone had only a modest protective effect 
which was not clearly concentration-dependent.  
 
The adenosine A1 receptor agonist N
6
-cyclopentyladenosine (CPA) produced a 75.4 + 3.2 % 
reduction in cell death when a supramaximal concentration (10 μM) was used. CPA was 
included to validate the assay and to provide context for any effects seen by the antioxidants 
tested, as we have previously shown CPA to be a potent protective agent in this model.
34, 53, 54
 
The higher concentrations of edaravone-TMIO 7 produced reductions in cell death at least as 
high as that of CPA and possibly higher, although the trend towards a greater effect of 100 
μM edaravone-TMIO 7 than CPA was not statistically significant. Thus, edaravone-TMIO 7 
was found to be a potent protective agent in a model of ischaemic cell death, with an activity 
equal to or greater than the potent cardioprotective agent CPA. 
 
 By comparison, edaravone 1 is used clinically for stroke patients twice a day with the dose 
of 30 mg for each treatment taking 30 minutes by intravenous infusion. An effective dose of 
3 mg/kg via intravenous infusion was reported against ischaemic brain injury models of 
rats.
56, 57
 Peak plasma concentrations of edaravone 1 from clinical trials of this agent have 
been reported to be around 20 μM after a moderate bolus intravenous dose (1.5 mg/kg).58 
Thus, the protective effects of edaravone analogues seen in the present study occurred at 
concentrations that were clinically relevant. 
 
Experimental 
General chemistry methods 
Air-sensitive reactions were carried out under an atmosphere of ultra-high purity argon. 5-
Bromo-1,1,3,3-tetramethylisoindoline-2-yloxyl,
59
 5-iodo-1,1,3,3-tetramethylisoindoline-2-
yloxyl 8
60
 and 5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl (CTMIO)
55
 were synthesised 
using established literature procedures. All other reagents were purchased from commercial 
suppliers and used without further purification. 
1
H and 
13
C NMR spectra were recorded on a 
Bruker Avance 400 spectrometer and referenced to the relevant solvent peak. Low and high 
resolution mass spectra were recorded at the Australian National University (ANU) using 
either a Micromass autospec double focusing magnetic sector mass spectrometer (EI+ 
spectra) or a Bruker Apex 3 fourier transform ion cyclotron resonance mass spectrometer 
with a 4.7 T magnet (ESI+ spectra). Formulations were calculated in the elemental analysis 
programs of Mass Lynx 4.0 or Micromass Opus 3.6. Fourier transform infrared (FTIR) 
spectra were recorded on a Nicolet 870 Nexus Fourier Transform Infrared Spectrometer 
equipped with a DTGS TEC detector and an ATR objective. Melting points were measured 
on a GallenKamp Variable Temperature Apparatus by the capillary method and are 
uncorrected. Analytical HPLC was carried out on an Agilent Technologies HP 1100 Series 
HPLC system using an Agilent Prep-C18 scalar column (4.6 × 150 mm, 10 μm) with a flow 
rate of 1 mL/min.  
 
Synthesis of 5-(3-methyl-pyrazol-5-ol-1-yl)-1,1,3,3-tetramethylisoindolin-2-yloxyl 7 
5-Iodo-1,1,3,3-tetramethylisoindolin-2-yloxyl 8 (300 mg, 0.95 mmol), 3-methyl-5-pyrazolone 
(124 mg, 1.27 mmol, 1.3 equiv.), 8-hydroxyquinoline (23 mg, 0.16 mmol, 17 mol%), CuI (30 
mg, 0.16 mmol, 17 mol%) and K2CO3 (160 mg, 1.16 mmol, 1.2 equiv.) were combined in a 
Schlenk tube. The tube was evacuated and an atmosphere of argon was introduced. DMSO (6 
cm
3
) was added and the reaction mixture submitted to three freeze-evacuate-thaw cycles after 
which time a positive pressure of argon was introduced. The reaction was heated at 95°C for 
8 hours. The resulting solution was diluted with EtOAc and run through a short silica column. 
The reaction residue was repeatedly extracted with EtOAc (3 × 10 cm
3
) and these organics 
were also run through the short silica column to remove insoluble impurities. Thorough 
elution with EtOAc ensured the desired compound eluted from the column. The combined 
column fractions were washed with H2O, dried (Na2SO4) and the solvent removed under 
reduced pressure to yield a dark brown residue. Silica gel chromatography (85:15, 
EtOAc:Hex) yielded 7 (36 mg, 0.126 mmol, 13.3%) as a pale yellow powder. mp 185°C 
(decomp.). MS (EI): m/z (%) = 286 (50) [M
+
]. HRMS (EI): m/z: calcd. for C16H20N3O2 [M
+
]: 
286.1556; found 286.1558. IR: 1430 cm
-1
 (N-O
•
). The purity of 7 was confirmed to be >96% 
using Analytical HPLC with a mobile phase of 60% MeOH/40% H2O. 
 
Synthesis of 5-(3-methyl-pyrazol-5-ol-1-yl)-2-methoxy-1,1,3,3-tetramethylisoindoline 10 
A solution of 5-(3-methyl-pyrazol-5-ol-1-yl)-1,1,3,3-tetramethylisoindolin-2-yloxyl 7 (44 
mg, 0.154 mmol) and FeSO4.7H2O (87 mg, 0.313 mmol, 2 equiv.) in DMSO (~1 cm
3
) was 
prepared. Hydrogen peroxide (30%, 35 μL, 0.37 mmol, 2.4 equiv.) was then added dropwise 
with stirring. After stirring at room temperature for 30 minutes, the reaction was quenched 
with H2O and extracted with EtOAc (3 × 30 cm
3
). The combined organics were dried 
(Na2SO4) and the solvent removed under reduced pressure. Silica gel column 
chromatography (70:30 EtOAc:Hex) yielded 10 (32 mg, 69%) as a brown solid. mp 198-
203°C (decomp.). 
1
H NMR (400 MHz, CDCl3): δ = 7.25 (dd, 1H, J1 = 7.2 Hz, J2 = 2.2 Hz, 6-
H), 7.17 (d, 1H, J1 = 7.2 Hz, 7-H) 7.10 (d, 1H, J2 = 2.2 Hz, 4-H), 5.60 (s, 1H, 4’-H), 3.81 (s, 
3H, O-CH3), 2.27 (s, 3H, 3’-CH3), 1.48 (s, 12H, 2 × C(CH3)2). 
13
C NMR (100 MHz, CDCl3): 
δ = 162.7 (C5’), 146.3 (C3’), 144.1 (C3a), 140.7 (C7a), 138.0(C5), 123.6 (C6), 122.2 (C7), 
118.1 (C4), 93.2 (C4’), 67.1 (C1/C3), 65.5 (O-CH3), 12.7 (N=C-CH3). MS (EI): m/z (%) = 
301 (25) [M
+
], 286 (100). HRMS (EI): m/z: calcd. for C17H23N3O2 [M
+
]: 301.1790; found 
301.1785. The purity of 10 was confirmed to be >96% using Analytical HPLC with a mobile 
phase of 60% MeOH/40% H2O. 
 
Method for Simulated Ischaemia 
Cell culture and stimulated ischaemia 
The H9c2(2-1) embryonic rat atrial cell line (American Type Culture Collection-ATCC, 
Manassas, VA, USA) was used for this study. The cell line was grown in Dulbecco’s 
modified Eagle’s medium containing 4 mM L-glutamate, 4.5 g/L glucose, 3.7 g/L sodium 
bicarbonate, 100 U/ml penicillin and 100 mg /ml streptomycin supplemented with 10% fetal 
bovine serum (Invitrogen, Mount Waverley, VIC, Australia) in a 5% CO2  incubator. Cells 
were used at 60-70 % confluence and plated one day prior to assay at 40000 cells per well of 
96 well plate. Simulated ischaemia was induced using conditions developed in our lab and 
described previously.
34, 53, 54
 In short, ischaemia was achieved by incubating the cells in 
hypoxic simulated ischaemia (SI) medium at pH 6.4 containing (in mM): 137 NaCl, 3.5 KCl, 
0.88 CaCl2.2H2O, 0.51 MgSO4.7H2O, 5.55 D-glucose, 4 HEPES, 10 2-deoxy-D-glucose and 
20 DL-lactic acid (Sigma, Castle Hill, NSW, Australia) plus 2% fetal bovine serum. Cells 
were incubated under nitrogen (100% N2 gas atmosphere) for 12 hrs at 37
o
C. Fresh simulated 
ischaemia medium was prepared for each experiment and sterile filtered prior to 
experimentation. Edaravone 1, edaravone-TMIO 7, edaravone-TMIO-Me 10 and CTMIO 
stock were dissolved in dimethyl sulfoxide and stored at -20°C. Each treatment was repeated 
in four independent assays performed in quadruplicate wells. Working solutions of 100, 10 
and 1 µM were achieved by dilution with freshly prepared SI buffer. 
 
Cell viability (PI) Assay and Imaging of H9C2 (2-1) Cells 
Detection of non-viable cells resulted from ischaemia is achieved by propidium iodide (PI) 
assay. 12 hours post stimulated ischaemia, cells was first washed with PBS and stained with 
50 µM PI (Sigma) in dark for 5 minutes, followed by PBS rinse twice prior to imaging. 
Images were taken using an inverted fluorescence microscope connected to SPOT RT camera 
(Nikon Eclipse TE2000U; Nikon Instruments, Tokyo, Japan) with DG-4 light box (Shutter 
Instruments, USA) and TRITC filter at 535 nm excitation and 617 nm emission. SI assay was 
repeated in at least 3 different passages, with each experimental group in triplicate and 4 
images were taken from each well to avoid localization.  PI-positive cells were quantified 
using ImageJ (NIH Image; National Institute of Health, USA). Percentage cell death was 
calculated by normalizing the PI-positive cells number to PI-positive cells of SI treatment. 
 
Statistical Analysis 
The effects of edaravone 1 and analogues on cardiomyoblast cell death during hypoxia were 
determined using a two-way analysis of variance (ANOVA), with one factor being 
antioxidant type and one factor being concentration. Identification of individual group-to-
group differences was performed using Bonferroni post-hoc analysis.  
 
Conclusions 
The protection of cells from ROS insult is an important therapeutic target during the acute 
phases of ischaemia. A novel antioxidant was designed for this purpose and combines 
edaravone 1, the free radical scavenger approved for use in ischaemic patients in Japan, with 
a nitroxide moiety. The synthesis of the target molecule was achieved by N-arylation of 3-
methyl-5-pyrazolone with 5-iodo-1,1,3,3-tetramethylisoindoline-2-yloxyl 8 in the presence of 
catalytic copper(I)iodide in DMSO in a low yield (13%). The use of 5-iodo-1,1,3,3-
tetramethylisoindoline, or the acetate protected nitroxide, 2-acetoxy-5-iodo-1,1,3,3-
tetramethylisoindoline, in place of 8 under the same reaction conditions failed to improve the 
yield of obtained product. Employing alternative reaction conditions involving Fe(acac)3, 
catalytic CuO and potassium carbonate in DMF surprisingly reduced the nitroxide to its 
secondary amine in good yield (74%). The methoxyamine derivative 10 was prepared from 7 
in good yield (69%) by reaction with methyl radicals formed using Fenton chemistry. 
Assessment of 7, its methoxyamine adduct 10 and 5-carboxy-1,1,3,3-tetramethylisoindolin-2-
yloxyl (CTMIO) against edaravone 1 in ischaemic rat atrial cardiomyocytes showed a 
significant decrease in cell death after prolonged ischaemia for all agents. The maximal 
protective effect was produced by treatment with nitroxide 7 at 100 μM with an observed cell 
death of 85.54 ± 2.13%. The concentration-dependent reduction in cell death by 7 after 12 
hours simulated ischaemia was significantly greater than that of edaravone 1 alone. 
Furthermore, the activity for 7 was found to be equal to or greater than the potent 
cardioprotective agent N
6
-cyclopentyladenosine (CPA). The methoxyamine derivative 10 and 
edaravone 1 showed no difference between the extent of reduction in cell death whilst 
CTMIO had only a modest protective effect which was not clearly-concentration dependent. 
Thus, the novel antioxidant 7 described herein shows promise for the treatment of 
cardiovascular ischaemia. Evaluation of this compound 7 as a potential treatment for 
ischaemic stroke is in progress and will be reported in due course.  
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